2 апр. 2016 г. · We report the results from the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A randomized trial, in which TAVR with a second- ...

29 янв. 2020 г. · The PARTNER 2 cohort A trial compared TAVR with surgical aortic-valve replacement in patients with severe, symptomatic aortic stenosis at ...

3 дек. 2017 г. · The 2016 Placement of Aortic Transcatheter Valves 2 (PARTNER 2) trial randomized 2032 patients with symptomatic severe AS at intermediate ...

13 окт. 2020 г. · The PARTNER 2A trial showed that TAVR is noninferior to SAVR for the primary endpoint at 2 years for the treatment of severe aortic stenosis in ...

28 апр. 2016 г. · Background: Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic- ...

The study results showed similar rates for death and neurological events in the TAVR and SAVR groups. The TAVR group was found to have a larger valve area.

PARTNER 2 Cohort A is a randomised controlled trial comparing TAVI and SAVR in 2,032 intermediate-risk patients with symptomatic severe aortic stenosis (aortic ...

Achieve your Higher Standard for what today's TAVR patients will need tomorrow. Low rates of SVD and SVD-related BVF at 5 years in the PARTNER II Trial2.

This clinical trial is for men and women who are diagnosed with severe aortic stenosis and are at intermediate-risk for traditional open-heart surgery for ...

PARTNER Trials outcome data. Overview of key landmark TAVI trials conducted with balloon expandable TAVI valves by Edwards Lifesciences.